StockData
SIGA Technologies Inc logo

SIGA Technologies Inc (SIGA) stock analysis

SIGANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3049% below fair value
$2.89−0.25 (-7.96%)

Close on Nov 12, 2026Market cap $207.65MP/E –Yield 20.76%

StockData Score

Prices as of Nov 11, 2026How the score works

Value3Growth0Performance2Health6Dividend3

Mixed14 of 30 checks passed

SIGA Technologies passes 14 of the 30 checks behind our score; 6 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
3/6
Growth
0/6
Past performance
2/6
Financial health
6/6
Dividend
3/6

What stands out

  • Margin of safety over 20%

    The price is 48.7% below fair value, more than the 20% cushion we look for.

  • Trading below fair value

    The share price of $3.14 is below our fair value estimate of $6.12.

  • No debt

    SIGA Technologies has no borrowings on its latest balance sheet.

  • Interest well covered

    No meaningful interest expense to cover.

What to watch

  • Return on equity under 15%

    Return on equity was 0.4% over the last twelve months and averaged 28.5% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -15.0%, below the 10% that usually covers the cost of capital.

  • Earnings shrank over 5 years

    Net income shrank 16.2% a year on average over the last five fiscal years.

  • Revenue growing under 10% a year

    Revenue grew -5.1% a year over the last three fiscal years, short of the 10% we look for.

Valuation3/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B below the industry

    SIGA Technologies's price-to-book of 1.38 is below the Drugs median of 2.29.

  • Trading below fair value

    The share price of $3.14 is below our fair value estimate of $6.12.

  • Margin of safety over 20%

    The price is 48.7% below fair value, more than the 20% cushion we look for.

Growth0/6
  • Revenue growing under 10% a year

    Revenue grew -5.1% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growing under 10% a year

    Diluted EPS grew -11.4% a year over the last three fiscal years.

  • Earnings growth not accelerating

    Net income grew -99.1% over the last twelve months, against a 5-year average of -16.2% a year.

  • Growing slower than the industry

    Revenue grew -69.6% over the last twelve months; the Drugs median is 8.0%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin slipping

    Gross margin was 54.0% over the last twelve months, against 76.3% a year earlier.

Past performance2/6
  • Return on equity under 15%

    Return on equity was 0.4% over the last twelve months and averaged 28.5% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -15.0%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    SIGA Technologies's return on equity of 0.4% is above the Drugs median of -58.9%.

  • Earnings shrank over 5 years

    Net income shrank 16.2% a year on average over the last five fiscal years.

  • Net margin below its 5-year average

    Net margin was 1.3% over the last twelve months, against a 5-year average of 39.7%.

  • Net margin above the industry

    SIGA Technologies's net margin of 1.3% is above the Drugs median of -53.0%.

Financial health6/6
  • No debt

    SIGA Technologies has no borrowings on its latest balance sheet.

  • Debt not rising

    With no debt today, leverage cannot have risen.

  • Debt covered by cash flow

    There is no debt to cover.

  • Interest well covered

    No meaningful interest expense to cover.

  • Short-term assets cover short-term debts

    Current assets are 24.57 times current liabilities.

  • Low bankruptcy risk

    The Altman Z-score is 15.02; above 3 is the safe zone and below 1.8 the distress zone.

Dividend3/6
  • Pays a dividend

    SIGA Technologies paid dividends worth 19.1% of the share price over the last twelve months.

  • Yield above Treasuries

    The 19.1% yield is above the 4.4% on a 1-year Treasury.

  • Yield in the top quarter

    The top quarter of US dividend payers yield 3.8% or more; SIGA Technologies yields 19.1%.

  • Dividend stability

    Fewer than five years of dividend history.

  • Not covered by earnings

    Dividends take 6325% of net income, leaving little room.

  • Cash-flow cover

    Needs dividends paid and free cash flow.

Scores of similar companies

Our estimate per share

$6.12

The share price is 49% below this estimate.

20%+ below
Near fair value
20%+ above
$3.14Price$6.12Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B2.5×2.8×2.3×$5.7929%
P/S4.2×3.7×4.8×$3.0829%
Earnings power10.4% cost of equity––$8.3643%
Fair value$6.12100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 9.2
  • Drugs median 25.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$1.68M
Value traded per 1% price move
$747.42K

Downside

High risk

Typical loss in a bad month
25.4%
Volatility (annualized)
44%
Sharpe ratio, 1 year
-1.27
Beta to the S&P 500 (5Y)
1.10

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

68.6%−19.6 pts over 5 years

Operating margin

25.1%−42.6 pts over 5 years

Net margin

24.6%−20.5 pts over 5 years

See a number that looks wrong?